Phathom Pharmaceuticals, Inc. (PHAT) vs Zevra Therapeutics, Inc. (ZVRA)
- Phathom Pharmaceuticals, Inc. PHAT 6.92 −7.73%
- Zevra Therapeutics, Inc. ZVRA 9.95 −3.12%
Phathom Pharmaceuticals, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. Phathom Pharmaceuticals, Inc. and Zevra Therapeutics, Inc. are of similar size ($609.9M and $606.8M). Phathom Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 10.5×. Zevra Therapeutics, Inc. grew revenue faster over the last twelve months: 119.4% against 110.2%. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs −41.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Zevra Therapeutics, Inc. leads on 11 and Phathom Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | PHAT | ZVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | 82.92% | 95.46% | 65.16% |
| Operating margin | (16.96%) | 60.54% | 0.00% |
| Net margin | (41.34%) | 42.25% | 0.00% |
| Free cash flow margin | (15.40%) | 24.30% | 0.00% |
| Return on equity | 26.42% | 34.33% | (56.36%) |
| Return on assets | (34.32%) | 20.57% | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack